Medically reviewed by Brian Bezack, DO Over-the-counter (OTC) inhalers are not approved for treating chronic obstructive ...

Labor & delivery. Pregnancy. Nursing mothers. Long-acting beta2-adrenergic agonists (LABA) as monotherapy (without inhaled corticosteroids [ICS]) for asthma can increase risk of asthma-related death.

Not studied in the relief of acute symptoms. Treat acute symptoms with an inhaled short-acting beta2-agonist. Prescribe an inhaled, short-acting beta2-agonist. Prior to initiation, patients who ...

The GoResp Digihaler – which delivers inhaled corticosteroid budesonide and long-acting beta agonist formoterol – has built-in sensors that detect and record data on a patient’s use and ...

a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer comparable or incremental ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium ... and formoterol fumarate, a long-acting beta2-agonist (LABA). European approval is based on the phase 3 PINNACLE trial, which ...

Among those patients who used a controller medication before starting an LABA, other controller medications were used more frequently than inhaled corticosteroids. We compared controller use ...